Trinity Biotech to Announce Q2 2024 Financial Results
Trinity Biotech plc (Nasdaq: TRIB), a commercial stage biotechnology company specializing in diabetes management solutions and human diagnostics, has announced it will release its Q2 2024 financial results on Wednesday, August 14, 2024.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Trinity Biotech plc (Nasdaq: TRIB), a commercial stage biotechnology company specializing in diabetes management solutions and human diagnostics, has announced it will release its Q2 2024 financial results on Wednesday, August 14, 2024. The company will host a conference call at 8:30 AM ET on the same day to discuss the results.
Investors and interested parties can access the call through various methods:
- US Toll-Free: 1-877-407-0784
- International: 1-201-689-8560
- Conference ID: 13748426
- Webcast link available
- Call me™ feature: https://callme.viavid.com/viavid/?callme=true&passcode=13743417&h=true&info=company-email&r=true&B=6
Positive
- Trinity Biotech is maintaining transparency by hosting a quarterly earnings call
- The company offers multiple ways for investors to access the financial results and participate in the call
Negative
- None.
Details
News Market Reaction – TRIB
The recorded move for TRIB in the trading session of this news was +2.85%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Conference Call Scheduled for Wednesday, August 14, 2024 at 8:30 AM ET
DUBLIN, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors, will report financial results for the second quarter 2024 on Wednesday, August 14, 2024 at 8:30 AM ET.
Conference Call Dial-In & Webcast Information
| Date: | Wednesday, August 14, 2024 |
| Time: | 8:30 AM ET |
| United States: | 1-877-407-0784 |
| International: | 1- 201-689-8560 |
| Conference ID: | 13748426 |
| Webcast: | webcast link |
| Call me™: | https://callme.viavid.com/viavid/?callme=true&passcode=13743417&h=true&info=company-email&r=true&B=6 |
About Trinity Biotech
Trinity Biotech is a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors. The Company develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market and has recently entered the wearable biosensor industry, with the acquisition of the biosensor assets of Waveform Technologies Inc. and intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. The products are used to detect infectious diseases and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells direct in the United States, Germany, France and the U.K. and through a network of international distributors and strategic partners in over 75 countries worldwide. For further information, please see the Company's website: www.trinitybiotech.com
| Contact: | Trinity Biotech plc | LifeSci Partners, LLC |
| John Gillard | Eric Ribner | |
| (353)-1-2769800 | (1)-646-751-4363 | |
| E-mail: john.gillard@trinitybiotech.com | E-mail: investorrelations@trinitybiotech.com |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.